{"filing":{"accession_number":"0001104659-26-091981","cik":"0001638287","ticker":"MTVA","company_name":"MetaVia Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"mtva-20260806x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806x8k.htm"},"events":[{"id":25429,"run_id":23081,"accession_number":"0001104659-26-091981","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"MetaVia issued a press release on August 6, 2026, announcing financial results for Q2 2026 ended June 30, 2026, including a net loss of $5.3 million ($0.90 per share), R\u0026D expenses of $3.5 million, G\u0026A expenses of $1.9 million, and a cash position of $12.6 million, along with clinical development milestones.","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26257,"accession_number":"0001104659-26-091981","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MetaVia issued a press release on August 6, 2026, announcing financial results for Q2 2026 ended June 30, 2026, including detailed operating expenses, net loss of $5.3 million, cash position of $12.6 million, and clinical development milestones. The filing explicitly states this is a disclosure of \"financial results for the second quarter ended June 30, 2026\" furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:41:10.930134+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26258,"accession_number":"0001104659-26-091981","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure incorporates by reference Exhibit 99.1, which is a press release announcing MetaVia's second quarter 2026 financial results, including R\u0026D expenses ($3.5M Q2 2026 vs. $2.3M Q2 2025), G\u0026A expenses ($1.9M vs. $2.0M), net loss ($5.3M or $0.90 per share vs. $4.0M or $2.87 per share), and cash position ($12.6M as of June 30, 2026). The filing explicitly states \"MetaVia Reports Second Quarter 2026 Financial Results\" and provides detailed condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release with material financial metrics.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:41:10.930134+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26257,"accession_number":"0001104659-26-091981","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MetaVia issued a press release on August 6, 2026, announcing financial results for Q2 2026 ended June 30, 2026, including detailed operating expenses, net loss of $5.3 million, cash position of $12.6 million, and clinical development milestones. The filing explicitly states this is a disclosure of \"financial results for the second quarter ended June 30, 2026\" furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:41:10.930134+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-08-06"},{"id":26258,"accession_number":"0001104659-26-091981","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure incorporates by reference Exhibit 99.1, which is a press release announcing MetaVia's second quarter 2026 financial results, including R\u0026D expenses ($3.5M Q2 2026 vs. $2.3M Q2 2025), G\u0026A expenses ($1.9M vs. $2.0M), net loss ($5.3M or $0.90 per share vs. $4.0M or $2.87 per share), and cash position ($12.6M as of June 30, 2026). The filing explicitly states \"MetaVia Reports Second Quarter 2026 Financial Results\" and provides detailed condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release with material financial metrics.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:41:10.930134+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-08-06"}]}